Jaffer Ajani (@jafferajanimd) 's Twitter Profile
Jaffer Ajani

@jafferajanimd

Professor, Department of Gastrointestinal Medical Oncology of MDACC, Chair of Gastric cancer and Esophageal cancer Panels of the NCCN

ID: 1534306038198960129

calendar_today07-06-2022 22:47:27

2 Tweet

96 Followers

62 Following

MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo
MD Anderson Cancer Center
@mdandersonnews

3 years ago

The U.S. FDA has approved two immunotherapy combinations for patients with advanced or metastatic esophageal cancer for whom surgery isn’t an option. Our Dr. Jaffer Ajani co-led the clinical trial, which led to the practice-changing approval: bit.ly/3a50l1W #EndCancer

The <a href="/US_FDA/">U.S. FDA</a> has approved two immunotherapy combinations for patients with advanced or metastatic esophageal cancer for whom surgery isn’t an option. Our Dr. Jaffer Ajani co-led the clinical trial, which led to the practice-changing approval: bit.ly/3a50l1W #EndCancer
Jaffer Ajani (@jafferajanimd) 's Twitter Profile Photo
Jaffer Ajani
@jafferajanimd

3 years ago

Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment gut.bmj.com/content/early/…